Clinical trial results:
A multi-center, randomized, double-blind, phase II trial with intraindividual comparison to assess superiority of Soventol HydroCortisonACETAT 1 % Cremogel versus vehicle on lesional skin in patients with mild atopic eczema, seborrheic eczema or stasis dermatitis and to assess safety of Soventol HydroCortisonACETAT 1 % Cremogel

Summary

EudraCT number	2017-000984-34
Trial protocol	DE
Global end of trial date	19 September 2018

Results information

Result version number	v1 (current)
This version publication date	18 April 2022
First version publication date	18 April 2022

Trial information

Trial identification

Sponsor protocol code	6630-9170-917016

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-
Other trial identifiers	bioskin trial no.: 370404BS

Notes:

Sponsors

Sponsor organisation name	MEDICE Arzneimittel Puetter GmbH & Co. KG
Sponsor organisation address	Kuhloweg 37, Iserlohn, Germany, 58638
Public contact	Medical Department, MEDICE Arzneimittel Puetter GmbH & Co. KG, +492371 9370, medinfo@medice.de
Scientific contact	Medical Department, MEDICE Arzneimittel Puetter GmbH & Co. KG, +492371 9370, medinfo@medice.de

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	13 May 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	19 September 2018
Global end of trial reached?	Yes
Global end of trial date	19 September 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess the superiority of Soventol HydroCortisonACETAT 1 % Cremogel versus vehicle and to assess safety of Soventol HydroCortisonACETAT 1 % Cremogel

Protection of trial subjects:

A specific treatment was to be discontinued if a treatment area showed worsening effects after one week of treatment. Since the appearance of the skin disease was described by several criteria (edema/papulation, oozing/crusts, excoriations, scaling and lichenification) discontinuation of special test areas was to be determined at the discretion of the investigator.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 January 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Germany: 52
Worldwide total number of subjects	52
EEA total number of subjects	52

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	47
From 65 to 84 years	5
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The participants were selected via advertisment and from the patient pool of the 4 selected trial sites

Pre-assignment

Screening details:

52 patients were randomized in this trial. 51 patients were with normal trial completion and 1 subject had discontinued the trial since exclusion criterion 10 was met .

Period 1

Period 1 title	overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	No
Arm title	Soventol HydroCortisonACETAT 1% Cremogel

Arm description:

Soventol HydroCortisonACETAT 1% Cremogel

Arm type	Experimental
Investigational medicinal product name	Soventol HydroCortisonACETAT 1% Cremogel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Cutaneous use

Dosage and administration details:

Up to 3 FTUs corresponding to approximately 1.5 g of the IMPs (Soventol HydroCortisonACETAT 1% Cremogel and the active ingredient-free vehicle) were applied to the respective treatment areas three times daily (morning, noon and evening) over a 2-week treatment period by the patient. The applied IMPs were distributed equally in the test areas using finger stalls. The time between the two applications should have included minimum 3 hours and maximum 18 hours.

Arm title	Placebo

Arm description:

Placebo

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Cutaneous use

Dosage and administration details:

Up to 3 FTUs corresponding to approximately 1.5 g (5) of the IMPs (Soventol HydroCortisonACETAT 1% Cremogel and the active ingredient-free vehicle) were applied to the respective treatment areas three times daily (morning, noon and evening) over a 2-week treatment period by the patient. The applied IMPs were distributed equally in the test areas using finger stalls. The time between the two applications should have included minimum 3 hours and maximum 18 hours.

Number of subjects in period 1	Soventol HydroCortisonACETAT 1% Cremogel	Placebo
Started	52	52
Completed	51	51
Not completed	1	1
Protocol deviation	1	1

Baseline characteristics

Reporting groups	
Reporting group title	overall trial

Reporting group description: -

Reporting group values	overall trial	Total	
Number of subjects	52	52	
Age categorical Units: Subjects			
Adults (18-64 years)	47	47	
From 65-84 years	5	5	
Gender categorical Units: Subjects			
Female	32	32	
Male	20	20	

Subject analysis sets	
Subject analysis set title	safety evaluation set
Subject analysis set type	Safety analysis

Subject analysis set description:

The safety analysis set comprised of all patients who recieved any IMP at least once.

Subject analysis set title	full analysis set
Subject analysis set type	Full analysis

Subject analysis set description:

The FAS included all randomized patients who received at least one dose of IMP, and had at least one post-baseline assessment

Subject analysis set title	valid case set
Subject analysis set type	Per protocol

Subject analysis set description:

The VCS included all patients of the FAS without any major protocol deviation, i.e. any deviation which conflicted with the trial aims.

Subject analysis set title	Posthoc subgroup
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Posthoc analyses focusing on a subgroup of patients only including patients with mild to moderate erythema (scores 2 and 3) were performed; excluding patients with baseline assessment ‘very mild erythema’

Reporting group values	safety evaluation set	full analysis set	valid case set
Number of subjects	52	52	50
Age categorical Units: Subjects			
Adults (18-64 years)	47	47	45
From 65-84 years	5	5	5
Gender categorical Units: Subjects			
Female	32	32	32
Male	20	20	18

Reporting group values	Posthoc subgroup		
Number of subjects	46		
Age categorical Units: Subjects			
Adults (18-64 years)	41		
From 65-84 years	5		
Gender categorical Units: Subjects			
Female	30		
Male	16		

End points

End points reporting groups

Reporting group title	Soventol HydroCortisonACETAT 1% Cremogel
Reporting group description:	
Soventol HydroCortisonACETAT 1% Cremogel	
Reporting group title	Placebo
Reporting group description:	
Placebo	
Subject analysis set title	safety evaluation set
Subject analysis set type	Safety analysis
Subject analysis set description:	
The safety analysis set comprised of all patients who recieved any IMP at least once.	
Subject analysis set title	full analysis set
Subject analysis set type	Full analysis
Subject analysis set description:	
The FAS included all randomized patients who received at least one dose of IMP, and had at least one post-baseline assessment	
Subject analysis set title	valid case set
Subject analysis set type	Per protocol
Subject analysis set description:	
The VCS included all patients of the FAS without any major protocol deviation, i.e. any deviation which conflicted with the trial aims.	
Subject analysis set title	Posthoc subgroup
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Posthoc analyses focusing on a subgroup of patients only including patients with mild to moderate erythema (scores 2 and 3) were performed; excluding patients with baseline assessment 'very mild erythema'	

Primary: Erythema Scores (full analysis set)

End point title	Erythema Scores (full analysis set)
End point description:	
End point type	Primary
End point timeframe:	
The severity of the lesions was clinically assessed by the blinded investigator on Days 1, 3, 8 and 15	

End point values	Soventol HydroCortisonACETAT 1% Cremogel	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	52	52		
Units: AUC				
arithmetic mean (standard error)	-13.0 (± 8.4)	-10.9 (± 9.6)		

Statistical analyses

Statistical analysis title	Erytheme Scores - AUC comparisons (FAS)
Comparison groups	Placebo v Soventol HydroCortisonACETAT 1% Cremogel
Number of subjects included in analysis	104
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1173
Method	Wilcoxon signed-rank test
Parameter estimate	Median difference (final values)
Point estimate	-2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.8
upper limit	1.3
Variability estimate	Standard deviation
Dispersion value	10.4

Primary: Erythema Scores - AUC comparison (valid case set)

End point title	Erythema Scores - AUC comparison (valid case set)

End point description:

End point type	Primary

End point timeframe:

The severity of the lesions was clinically assessed by the blinded investigator on Days 1, 3, 8 and 15

End point values	Soventol HydroCortisonACETAT 1% Cremogel	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	50	50		
Units: AUC				
arithmetic mean (standard deviation)	-13.1 (± 8.5)	-10.5 (± 9.6)		

Statistical analyses

Statistical analysis title	Erythema Scores - AUC comparison (VCS)
Comparison groups	Soventol HydroCortisonACETAT 1% Cremogel v Placebo

Number of subjects included in analysis	100
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0486
Method	Wilcoxon signed-rank test
Parameter estimate	Median difference (final values)
Point estimate	-2.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.8
upper limit	0
Variability estimate	Standard deviation
Dispersion value	10.3

Primary: Erythema Scores - AUC comparison (post hoc analysis)

End point title	Erythema Scores - AUC comparison (post hoc analysis)
End point description:	
End point type	Primary
End point timeframe:	
The severity of the lesions was clinically assessed by the blinded investigator on Days 1, 3, 8 and 15	

End point values	Soventol HydroCortisonACETAT 1% Cremogel	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	46	46		
Units: AUC				
arithmetic mean (standard deviation)	-14.1 (± 8.0)	-11.2 (± 10.1)		

Statistical analyses

Statistical analysis title	Erythema Scores - AUC comparison (post hoc)
Comparison groups	Soventol HydroCortisonACETAT 1% Cremogel v Placebo
Number of subjects included in analysis	92
Analysis specification	Post-hoc
Analysis type	superiority
P-value	= 0.0349
Method	Wilcoxon signed-rank test
Parameter estimate	Median difference (final values)
Point estimate	-2.9

Confidence interval	
level	95 %
sides	2-sided
lower limit	-6
upper limit	0
Variability estimate	Standard deviation
Dispersion value	10.8

Adverse events

Adverse events information	
Timeframe for reporting adverse events: AEs were recorded throughout the entire trial	
Assessment type	Systematic

Dictionary used	
Dictionary name	MedDRA
Dictionary version	21.0

Reporting groups	
Reporting group title	all subjects

Reporting group description: -

Serious adverse events	all subjects		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 52 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	all subjects		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	4 / 52 (7.69%)		
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	4 / 52 (7.69%)		
occurrences (all)	4		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported